Basilea Pharmaceutica First Half 2024 Earnings: EPS Beats Expectations

Basilea Pharmaceutica (VTX:BSLN) First Half 2024 Results

Key Financial Results

• Revenue: CHF76.3m (down 10% from 1H 2023).
• Net income: CHF20.7m (down 35% from 1H 2023).
• Profit margin: 27% (down from 38% in 1H 2023). The decrease in margin was primarily driven by lower revenue.
• EPS: CHF1.72 (down from CHF2.66 in 1H 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Basilea Pharmaceutica EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 71%.

Looking ahead, revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.

Performance of the market in Switzerland.

The company's shares are up 17% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Basilea Pharmaceutica that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.